Biotech behemoth Takeda moving to Boston

Biotech giant Takeda Pharmaceutical Co. will move its U.S. headquarters on the Boston area through the current offices near Chicago, the company said, as it prepares to purchase Shire Plc inside of a deal likely to close pick up.

“This move, while difficult, permits closer collaboration across Takeda to best position our future pipeline for fulfillment. It’ll also simplify our existing Takeda U.S. operations,” said Julia Ellwanger, a Takeda spokeswoman. “In determining where i’d locate, we’ve viewed several factors, like the evolution of Takeda’s portfolio, being much better where our future pipeline has generated, and having Takeda U.S. business units together to produce opportunities for employees to develop their careers across our large, diverse business.”

Takeda has roughly 1,000 employees in Deerfield, Ill., a Chicago suburb.

Takeda’s merger with Shire is already likely to make the combined company the greatest biotech employer in Massachusetts, combining Takeda’s 2,150 local employees approximately 3,000 Shire employees. Ellwanger stated it is unclear how many jobs Takeda will add in Massachusetts.

“Several of the employees currently located in the Deerfield office is going to be offered job offers and/or relocation opportunities,” she said.

Earlier this current year, Takeda opted for purchase Shire for $62 billion. The sale still could use a number of approvals before it could close, but FTC regulators approved the deal above the summer. Other jurisdictions all over the world will have to give their own individual approvals ahead of the companies can close purchasing. The purchase is supposed to turn Takeda right global pharmaceutical powerhouse.

“Shire’s highly complementary product portfolio and pipeline, in addition to experienced employees, will accelerate our transformation for your stronger Takeda,” Takeda us president Christophe Weber said in a statement a few months ago. “Together, i will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies.”

Even if ever the deal falls apart, Ellwanger said, Takeda still offers move its headquarters for the Boston area.

Also yesterday, Shire pulled out of an commitment originally created in 2016 to transfer in to a 350,000-square-foot building at 500 Kendall St. in Cambridge, as per the Boston Business Journal. Shire would not interact with requests for comment, plus its unclear issue move is about Takeda’s announcement.

Always a biotech mecca, the Boston area has added an increasing number of biotech jobs a lot. Cambridge has little — if any — room left choosing labs, and developers have started proposing and building new developments supposed to attract biotech and pharmaceutical companies in portions of Boston, for example the Seaport District.

Related posts

Lebron says in Kaepernick reference: I stand with Nike


Tesla stock falls as CEO Elon Musk may seem to smoke marijuana on video


Wynn Resorts facing slew of challenges


Leave a Comment

Skip to toolbar